GlassScriptPhysician profile
Mudassar Tariq
NPI 1588895825
$9,335.01
in general payments reported to CMS, 2019-2025
19 companies · $2,641 in 2025
The $2,641 reported for 2025 was more than what 95% of Child & Adolescent Psychiatry providers received nationally (typical 2025 total: $132).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $522 · 2020: $139 · 2021: $555 · 2022: $1,512 · 2023: $1,857 · 2024: $2,109 · 2025: $2,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,565 · Education: $42.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,564.53 |
| Education | $42.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,051.32 | 2022-2025 | Caplyta |
| Abbvie INC. | $1,384.10 | 2021-2025 | Vraylar |
| Alkermes, INC. | $1,203.11 | 2019-2025 | Lybalvi, Aristada |
| Axsome Therapeutics, INC. | $885.04 | 2022-2025 | Auvelity |
| Supernus Pharmaceuticals, INC. | $717.26 | 2021-2025 | Qelbree, Qelbree |
| Corium, LLC | $615.98 | 2021-2025 | Azstarys, Azstarys |
| E.R. Squibb & Sons, L.L.C. | $540.44 | 2025 | Cobenfy |
| Otsuka America Pharmaceutical, INC. | $428.02 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $387.18 | 2021-2025 | Trintellix |
| Allergan, INC. | $242.04 | 2019-2020 | |
| Indivior INC. | $173.26 | 2019-2024 | Sublocade |
| Neurocrine Biosciences, INC. | $152.42 | 2022-2025 | Ingrezza |
| Ironshore Pharmaceuticals INC. | $140.82 | 2020-2023 | Jornay Pm |
| Teva Pharmaceuticals USA, INC. | $134.64 | 2019 | |
| Vanda Pharmaceuticals INC. | $124.99 | 2024 | Fanapt |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tris Pharma INC | $58.98 | 2022-2024 | Dyanavel Xr |
| Lundbeck LLC | $46.76 | 2022 | |
| Janssen Pharmaceuticals, INC | $24.33 | 2025 | Spravato |
| Brainsway USA INC | $24.32 | 2024 | Brainsway Deep Tms System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mudassar Tariq listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.